Aeterna Zentaris taps Ergomed for Phase III study; FDA revamps REMS site;

> Aeterna Zentaris ($AEZS) picked CRO Ergomed to help run a Phase III trial of its macimorelin, designed to treat adult growth hormone deficiency. More

> The FDA has overhauled its Risk Evaluation and Mitigation Strategies (REMS) website to make it easier to find up-to-date information. News

Suggested Articles

Genesis Drug Discovery & Development has bought up New England Discovery Partners as it looks to boost its synthetic and medicinal chemistry.

Sanofi plans to incorporate its real-world data platform with Aetion’s analytics system to better develop studies for regulatory decision-making.

Major CRO player Pharmaceutical Product Development is set to go back on the public markets after announcing its IPO plans.